Crystalys Therapeutics
PrivateLast Round
Series B
Jul 22, 2026
Est. Valuation
$280M
Total Funding Raised
$358M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Crystalys Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in July 2026.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing dotinurad, a next-generation URAT1 inhibitor, as a second-line therapy for gout.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Crystalys Therapeutics Comparables
Compare Crystalys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LG Chem | 78% | |
| Simcere Pharmaceutical Group | 76% | |
| ApicHope Pharmaceutical Group Co.,Ltd. | 75% |
For institutional investors. Book with your work email.
Crystalys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 22, 2026 | ||||
| Series A | Sep 30, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Crystalys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series B |
| Conrad Prebys Foundation | Series A |
| Prebys Ventures | Series B |
| Wedbush Healthcare Partners | Series A |
| Perceptive Advisors | Series B, Series A |
| KB Investment | Series B, Series A |
| Lightstone Ventures | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 28, 2026
Grew 28% QoQ, from 18 to 23 employees.
- Aug 22, 2026
Monthly visitors increased 38% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 23, 2026
Crystalys Therapeutics Inc. appoints pharmaceutical industry veteran Seth H.Z. Fischer as a director representing Catalys Pacific as it advances gout drug candidate dotinurad through global Phase 3 development in California on Sep 23rd '26.
- hiresSep 23, 2026
Crystalys Therapeutics Inc. appointed Tim Walbert, former Chairman, President and CEO of Horizon Therapeutics, to its board as an Independent Director in California on Feb 11th '26.
- promotesSep 23, 2026
Crystalys Therapeutics Inc. promotes co-founder DeAnne Reid to Chief Administrative Officer as it expands its executive leadership team and scales operations in California on Sep 23rd '26.
For institutional investors. Book with your work email.
Crystalys Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Crystalys Therapeutics's valuation, stock price, and market status.
Is Crystalys Therapeutics a public or private company?
Crystalys Therapeutics is a private company.
What is the current stock price of Crystalys Therapeutics?
Crystalys Therapeutics is a private company, so its shares have no public market price. Caplight tracks Crystalys Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Crystalys Therapeutics worth (valuation)?
Crystalys Therapeutics's valuation is estimated at $280.0M based on funding round data.
Can I buy Crystalys Therapeutics stock?
Crystalys Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Crystalys Therapeutics's last funding round?
Crystalys Therapeutics's most recent funding round was Series B on July 22, 2026.
Who are the main investors in Crystalys Therapeutics?
Key investors in Crystalys Therapeutics include Frazier Life Sciences, Novo Holdings, Catalys Pacific, SR One.
Will Crystalys Therapeutics IPO soon?
No public IPO plans have been announced for Crystalys Therapeutics.
How can I track Crystalys Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Crystalys Therapeutics's shares on secondary markets.